NASDAQ$RLMD
Relmada Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Relmada Therapeutics reported financial results and provided a corporate update.
Relmada Therapeutics reported their Q4 and full-year 2020 financial results, highlighting the initiation of their Phase 3 program for REL-1017 and anticipating multiple data readouts over the next several quarters. The company also reported a strong balance sheet to drive development efforts.
- Phase 3 program for REL-1017 as adjunctive treatment for major depressive disorder was initiated.
- Multiple data readouts are anticipated over the next several quarters.
- The company has a strong balance sheet driving development efforts.
- First of two Phase 3 trials, RELIANCE I, is enrolling as planned, and RELIANCE II is expected to begin imminently.
Headline financials
Revenue & EPS history
Relmada · Revenue · Quarterly
-$9.87K
Forward guidance
Relmada Therapeutics anticipates multiple key data readouts over the next several quarters, including data from the oxycodone human abuse potential study in Q2 2021, followed by data from the IV ketamine human abuse potential study by year-end 2021. Top-line data from both RELIANCE I and RELIANCE II is expected in the first half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2020
-1.6%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+3.2%
Avg return
30 days after
35%
15 / 43 earnings
Positive
+10.8%
Q4 2024
Best reaction
-29.0%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -12.5% | — | |
| Q1 2026 | +1.2% | -6.1% | -11.4% | |
| Q3 2025 | +1.8% | +7.7% | +4.6% | |
| Q2 2025 | -2.5% | -5.6% | +174.1% | |
| Q1 2025 | +6.6% | +33.4% | +53.6% | |
| Q4 2024 | +10.8% | -5.1% | +33.2% | |
| Q3 2024 | -3.5% | -2.9% | -86.5% | |
| Q2 2024 | -29.0% | -29.0% | -25.9% | |
| Q1 2024 | -0.5% | -7.6% | -22.8% | |
| Q4 2023 | -19.6% | -12.0% | -22.1% | |
| Q3 2023 | -2.0% | -7.5% | -16.1% | |
| Q2 2023 | +3.0% | +17.4% | +34.5% | |
| Q1 2023 | -9.2% | -10.7% | -19.0% | |
| Q4 2022 | -3.0% | +4.3% | +12.8% | |
| Q3 2022 | +10.4% | +2.3% | -53.5% | |
| Q2 2022 | -0.7% | -2.8% | +8.9% | |
| Q1 2022 | -12.4% | -18.5% | -20.1% | |
| Q4 2021 | +7.5% | +10.4% | +4.9% | |
| Q3 2021 | -8.2% | -12.0% | -24.4% | |
| Q2 2021 | +4.8% | +0.6% | +13.6% | |
| Q1 2021 | -4.1% | +0.0% | -10.9% | |
| Q4 2020 | -10.4% | -7.4% | +4.3% | |
| Q3 2020 | +0.0% | +8.3% | +0.9% | |
| Q2 2020 | -0.3% | +7.7% | +0.0% | |
| Q1 2020 | +9.6% | +8.5% | +12.6% | |
| Q4 2019 | -0.1% | -1.7% | +19.7% | |
| Q3 2019 | -3.0% | -5.1% | +29.9% | |
| Q2 2019 | -4.0% | -8.5% | +106.8% | |
| Q1 2019 | +0.0% | +1.7% | +13.9% | |
| Q3 2018 | +5.1% | +2.6% | -1.7% | |
| Q1 2018 | -5.0% | +5.3% | -13.3% | |
| Q2 2018 | +0.0% | -2.1% | -3.5% | |
| Q4 2017 | +4.7% | +4.7% | -11.0% | |
| Q3 2017 | -2.0% | -2.0% | -20.6% | |
| Q2 2017 | -8.6% | -4.8% | -32.9% | |
| Q1 2017 | +7.4% | +0.0% | -19.3% | |
| Q3 2016 | -17.8% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -1.1% | — | — | |
| Q3 2015 | -2.5% | — | — | |
| Q2 2014 | +4.2% | — | — | |
| Q3 2014 | -4.6% | — | — | |
| Q1 2015 | +5.9% | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro